Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC

被引：9
|
作者：
Piotrowska, Zofia
Liu, Stephen V.
Muzikansky, Alona
Marcoux, Nicolas
Banwait, Mandeep
Stevens, Sara
Goodwin, Kelly
Lafferty, Tracey E.
Ackil, Jennifer
Krueger, Elizabeth A.
Heist, Rebecca Suk
Lin, Jessica Jiyeong
Gainor, Justin F.
Hata, Aaron N.
Shaw, Alice Tsang
Sequist, Lecia V.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Harvard Med Sch, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21231
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21231
引用
收藏
页数：2
相关论文
共 50 条
  • [21] INSIGHT 2: Tepotinib plus Osimertinib in EGFR-Mutant NSCLC with Resistance to 1st-Line Osimertinib due to MET Amplification
    Smit, E.
    Felip, E.
    Karachaliou, N.
    Ellers-Lenz, B.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S36 - S36
  • [22] OSIMERTINIB MAY BE AN EFFECTIVE FIRST-LINE THERAPY IN EGFR-MUTANT NSCLC
    不详
    CANCER DISCOVERY, 2017, 7 (10) : 1061 - 1061
  • [23] Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
    Piotrowska, Zofia
    Hata, Aaron N.
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2441 - 2443
  • [24] Tepotinib plus osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
    Wu, Y-L.
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul Shukor, S.
    Tho, L. M.
    Wang, C-C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E. F. F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1036 - S1036
  • [25] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
    Kim, T. M.
    Guarneri, V.
    Jye, V. P.
    Khaw, L. B.
    Yang, J. -J.
    Wislez, M.
    Huang, C.
    Kin, L. Chong
    Mazieres, J.
    Tho, L. M.
    Hayashi, H.
    Nhung, N.
    Chia, P. L.
    De Marinis, F.
    Raskin, J.
    Zhou, Q.
    Finochhiaro, G.
    Le, X.
    Tan, D.
    Brutlach, S.
    O'Brate, A.
    Adrian, S.
    Berghoff, K.
    Ellers-Lenz, B.
    Karachaliou, N.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S94 - S94
  • [26] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Yang, Jin-ji
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kin
    Mazieres, Julien
    Tho, Ye Mun
    Hayashi, Hidetoshi
    Nhung Nguyen
    Chia, Puey Ling
    de Marinis, Filippo
    Raskin, Jo
    Zhou, Qinghua
    Finocchiaro, Giovanna
    Le, Xiuning
    Tan, Daniel
    O'Hara, Richard M., Jr.
    Brutlach, Sabine
    O'Brate, Aurora
    Adrian, Svenja
    Berghoff, Karin
    Ellers-Lenz, Barbara
    Karachaliou, Niki
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E38 - E38
  • [27] Tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis
    Le, Xiuning
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Yang, Jinji
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kim
    Mazieres, Julien
    Lye Mun Tho
    Hayashi, Hidetoshi
    Nguyen Nhung
    Chia, Puey Ling
    De Marinis, Fillippo
    Raskin, Jo
    Zhou, Qinghua
    Finochhiaro, Giovanna
    Tan, Daniel
    Brutlach, Sabine
    O'Brate, Aurora
    Adrian, Svenja
    Berghoff, Karin
    Ellers-Lenz, Barbara
    Karachaliou, Niki
    Wu, Yi-Long
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [28] The continued osimertinib plus chemotherapy overcoming resistance after histologic transformation in EGFR-mutant lung adenocarcinoma treated with osimertinib.
    Kang, Jin
    Li, Xiang-Meng
    Cheng, Jia-Tao
    Chen, Huajun
    Zhang, Xuchao
    Tu, Hai-Yan
    Zhou, Qing
    Wu, Yi-Long
    Yang, Jin-Ji
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis
    Shih, J-Y.
    Wang, J.
    Wang, Y.
    Wang, J.
    Lee, S-H.
    Azuma, K.
    Takahashi, T.
    Tan, J-L.
    Lin, C. C.
    Ganguly, S.
    Lee, V. H. F.
    Chu, P-L.
    Shah, S.
    Diorio, B.
    Bauml, J. M.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1661 - S1662
  • [30] Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
    Gettinger, Scott
    Hellmann, Matthew D.
    Chow, Laura Q. M.
    Borghaei, Hossein
    Antonia, Scott
    Brahmer, Julie R.
    Goldman, Jonathan W.
    Gerber, David E.
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott A.
    Young, Tina C.
    Li, Xuemei
    Geese, William J.
    Rizvi, Naiyer
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1363 - 1372
12345